Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 235

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 235
---
 pipelineM1 (Lead selection), M2 (Candidate selection), First in Human,Pivotal Studies, Submissions, Approvals                                       | 15.0% |
| CSRPeople & Culture, Environment, Governance (efficient ExecutiveCommittee operations and effective Board interactions)                                             | 10.0% | CSRPeople & Culture, Environment, Governance (reinforcement of thestrategic dialogue with the Board of Directors and functioning ofthe new Executive Committee) | 10.0% |

(*) For details of individual objectives for 2024 refer to "— Compensation and benefits of all kinds paid during 2024 or awarded in respect of 2024 to Paul Hudson, Chief Executive Officer" below. Equity-based compensation Acting on a recommendation from the Compensation Committee and within the limits set out in the Chief Executive Officer's compensation policy, the Board of Directors meeting of February 12, 2025 proposes awarding 90,000 performance shares to Paul Hudson in respect of 2025. In accordance with the AFEP-MEDEF Code, the entire award will be subject to criteria that are both internal and external. Given the proposed increase in the number of performance shares awarded in respect of 2025 (see "— Compensation Policy for the Chief Executive Officer" above), the Board of Directors decided, on a recommendation from the Compensation Committee, to raise the proportion based on the external criterion ( TSR) from 20% to 30% for the Chief Executive Officer (see below). T o enable this, the Business EPS weighting would reduce from 35% to 30%, and the FCF weighting from 25% to 20%; the R&D and CSR criteria would remain unchanged. The criteria applied to the Chief Executive Officer's 2025 performance share plan are as follows: • internal criteria, based on Business EPS 30%, FCF 20%, R&D pipeline 10%, and CSR criteria 10%; and • an external criterion (accounting for 30%) based on the level of TSR as compared with that of a panel of 12 leading global pharmaceutical companies: Amgen, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Inc., Eli Lilly and Company Inc., GlaxoSmithKline plc, Johnson & Johnson Inc., Merck Inc., Novartis AG, Novo Nordisk, Pfizer Inc., and Roche Holding Ltd. Any TSR-linked payment is contingent on Sanofi achieving an Endpoint Rank greater than or equal to the median of the TSR panel. To achieve